IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 11,172 shares of the company’s stock after selling 476 shares during the quarter. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $5,443,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of IDXX. Avantax Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 21.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 632 shares of the company’s stock valued at $351,000 after purchasing an additional 110 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in IDEXX Laboratories by 2.8% during the fourth quarter. Panagora Asset Management Inc. now owns 1,523 shares of the company’s stock worth $845,000 after acquiring an additional 41 shares during the period. Clearbridge Investments LLC raised its position in IDEXX Laboratories by 1.0% in the fourth quarter. Clearbridge Investments LLC now owns 42,842 shares of the company’s stock worth $23,779,000 after acquiring an additional 405 shares in the last quarter. D.A. Davidson & CO. lifted its holdings in IDEXX Laboratories by 4.4% in the fourth quarter. D.A. Davidson & CO. now owns 1,509 shares of the company’s stock valued at $838,000 after acquiring an additional 64 shares during the period. Finally, Quest Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth $500,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research analyst reports. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target for the company. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, Piper Sandler reduced their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $506.74 on Friday. The business’s 50-day moving average price is $483.85 and its 200 day moving average price is $499.57. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a market capitalization of $41.85 billion, a PE ratio of 49.06, a price-to-earnings-growth ratio of 4.17 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business posted $2.67 earnings per share. IDEXX Laboratories’s revenue was up 6.4% on a year-over-year basis. On average, research analysts predict that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.